U.S. Physical Therapy has delivered mixed results for long term holders, with the share price down 21.3% over 5 years despite a recent uptick. This puts fresh focus on whether the current US$82.47 level lines up with the cash the business can generate. With the stock back in positive territory over the past year and new leadership in the finance seat, the question now is how well those cash flows support today's valuation.
-
The share price decline of 21.3% over 5 years means anyone looking at U.S. Physical Therapy now is effectively asking whether the underlying cash generation story has lagged behind that move or simply not kept up with prior expectations.
-
The appointment of Nchacha Etta as Chief Financial Officer, alongside expansion through acquisitions and hospital partnerships, and with margin pressures and higher credit facility borrowings in the background, may shape how quickly the company can translate its growth plans into steady free cash flow for shareholders.
-
What if you looked at U.S. Physical Therapy through its sales instead? See why U.S. Physical Therapy's 1.5x P/S tells a different valuation story .
The issue now is whether the stock's current price is well supported by its cash flows when viewed through a Discounted Cash Flow (DCF) lens.
If you want more context around U.S. Physical Therapy and its cash flow story, compare it with other businesses using 35 high quality undervalued stocks
Is U.S. Physical Therapy a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach estimates what U.S. Physical Therapy might be worth based on the cash it can generate for investors over time. The model starts with last twelve month free cash flow of about $68.5m and then assumes free cash flow grows gradually over the coming decade rather than rising sharply or declining.
On those assumptions, the DCF outcome sits substantially above the current share price of $82.47, which suggests the market is not fully reflecting the projected cash stream. The recent appointment of Nchacha Etta as CFO, arriving as the business balances acquisition driven expansion with margin and borrowing pressure, helps explain why investors are still cautious even though the cash flow projections support a higher intrinsic worth. Find out what U.S. Physical Therapy could be worth using our Discounted Cash Flow (DCF) estimate .
The U.S. Physical Therapy Narrative: What Would Justify Today's Price?
Simply Wall St Narratives are the link between U.S. Physical Therapy's DCF outcome and the current share price. They spell out which paths for growth, margins and earnings would need to play out for the valuation to look far higher or materially lower than where the stock trades today, and they sit on the company's Community page. Each scenario ties its number to a clear view of how U.S. Physical Therapy's performance and risks might evolve, which you can revisit as new information comes through.
One of the top community narratives on U.S. Physical Therapy: 12% undervalued
"Rising patient demand, efficient operations, and acquisitions in key regions drive sustained revenue and margin growth, strengthening the company's earnings outlook..."
Discover why this Narrative puts U.S. Physical Therapy at 12% undervalued .
U.S. Physical Therapy's valuation still leaves one critical angle unexplored
Price and cash generation only tell part of the U.S. Physical Therapy story, since our research has also highlighted specific areas of concern that informed investors usually review before committing fresh capital. Take a closer look at 2 warning signs before settling on a valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include USPH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
